Score Overview
Explore the 2021 public Archive ranking →
Where Rigel Pharmaceuticals Inc has ranked, year by year
Showing 10 years ranking history by HDB Score.
Has not reached the top 50 on HDB Score in any year we have ranked.
- RIGL
2011: 71.9% · 2021: 85.8% · free through 2021 · longest runs
Net Income x Stock Price
Historical Returns
| Period | Price | Return |
|---|---|---|
Last Price2026-09-29 | $ 48.89 | — |
1 Year2025-09-29 | $ 28.75 | 70.05% |
5 Years2021-09-29 | $ 36.30 | 34.68% |
10 Years2016-09-29 | $ 35.70 | 36.95% |
20 Years2006-09-29 | $ 102.70 | -52.40% |
All Time2000-11-29 | $ 639.84 | -92.36% |
| Period | Last Price2026-09-29 | 1 Year2025-09-29 | 5 Years2021-09-29 | 10 Years2016-09-29 | 20 Years2006-09-29 | All Time2000-11-29 |
|---|---|---|---|---|---|---|
| Price | $ 48.89 | $ 28.75 | $ 36.30 | $ 35.70 | $ 102.70 | $ 639.84 |
| Return | — | 70.05% | 34.68% | 36.95% | -52.40% | -92.36% |
Prices are split & dividend adjusted. All values are reported in USD.
Fundamental Data
Reported in USD
| Year | |||
|---|---|---|---|
| TTM | $ 276M | $ 321M | $ 95M |
| 2025 | $ 294M | $ 367M | $ 154M |
| 2024 | $ 179M | $ 17M | $ 77M |
| 2023 | $ 116M | -$ 25M | $ 56M |
| 2022 | $ 120M | -$ 58M | $ 58M |
| 2021 | $ 149M | -$ 17M | $ 124M |
| 2020 | $ 108M | -$ 29M | $ 57M |
| 2019 | $ 59M | -$ 66M | $ 98M |
| 2018 | $ 44M | -$ 70M | $ 128M |
| 2017 | $ 4M | -$ 77M | $ 115M |
| 2016 | $ 20M | -$ 69M | $ 74M |
| 2015 | $ 28M | -$ 51M | $ 126M |
| 2014 | $ 8M | -$ 90M | $ 143M |
| 2013 | $ 7M | -$ 89M | $ 211M |
| 2012 | $ 2M | -$ 98M | $ 298M |
| 2011 | $ 4M | -$ 85M | $ 247M |
| 2010 | $ 125M | $ 37M | $ 177M |
| 2009 | $ 750K | -$ 111M | $ 133M |
| 2008 | -$ 132M | $ 134M | |
| 2007 | $ 12M | -$ 74M | $ 108M |
| 2006 | $ 33M | -$ 37M | $ 104M |
| 2005 | $ 16M | -$ 45M | $ 138M |
| 2004 | $ 4M | -$ 56M | $ 71M |
| 2003 | $ 11M | -$ 41M | $ 46M |
| 2002 | $ 15M | -$ 37M | $ 27M |
| 2001 | $ 15M | -$ 23M | $ 33M |
| IPO2000 | $ 13M | -$ 25M | $ 52M |
Rigel Pharmaceuticals Inc fundamental performance
Between 2020 and 2025, revenue grew from $ 108M to $ 294M and net income went from -$ 29M to $ 367M. Revenue increased in 2 of those 5 years; net income in 3.
Between 2015 and 2025, revenue grew from $ 28M to $ 294M and net income went from -$ 51M to $ 367M. Revenue increased in 6 of those 10 years; net income in 7.
Rigel Pharmaceuticals Inc currently holds a 20-year HDB Score of 4.7 out of 10. How the HDB Score is calculated.
Membership
Continue RIGL’s history
The public Archive runs through 2021. Membership adds recent and current rankings.
- Recent and current rankings across 3,814 companies
- Compare companies with the latest data
- Track your research shortlist in a portfolio
